Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease

Kidney International

Volumn 92, Issue 2, 2017, Pages 306-312

  Sugahara, Mai ^a   Tanaka, Tetsuhiro ^a   Nangaku, Masaomi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

anemia; erythropoietin; hypoxia inducible factor; prolyl hydroxylase domain

Indexed keywords

ANTIANEMIC AGENT; DAPRODUSTAT; EPOETIN BETA PEGOL; HYPOXIA INDUCIBLE FACTOR; IRON; MOLIDUSTAT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYL HYDROXYLASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; ROXADUSTAT; UNCLASSIFIED DRUG; VADADUSTAT; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1;

ANEMIA; CARCINOGENESIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ERYTHROPOIESIS; HEMODIALYSIS; HUMAN; IRON METABOLISM; KIDNEY FIBROSIS; LOW DRUG DOSE; NONHUMAN; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEIOTROPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL (TOPIC); COMPLICATION; METABOLISM;

ANEMIA; CLINICAL TRIALS AS TOPIC; ERYTHROPOIETIN; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IRON; PROLYL-HYDROXYLASE INHIBITORS; RENAL INSUFFICIENCY, CHRONIC;

EID: 85021195196     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2017.02.035     Document Type: Short Survey

References (40)

1. Singh, A.K., Szczech, L., Tang, K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006), 2085–2098.
2. Drüeke, T.B., Locatelli, F., Clyne, N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006), 2071–2084.
3. Pfeffer, M.A., Burdmann, E.A., Chen, C.Y., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 (2009), 2019–2032.
4. Koury, M.J., Haase, V.H., Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol 11 (2015), 394–410.
5. Maxwell, P.H., Eckardt, K.U., HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol 12 (2016), 157–168.
6. Rosenberger, C., Mandriota, S., Jürgensen, J.S., et al. Expression of hypoxia-inducible factor-1α and -2α in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 13 (2002), 1721–1732.
7. Gruber, M., Hu, C.J., Jonson, R.S., et al. Acute postnatal ablation of Hif-2α results in anemia. Proc Natl Acad Sci USA 104 (2007), 2301–2306.
8. + cells. Pflugers Arch 468 (2016), 1479–1487.
9. Percy, M.J., Furlow, P.W., Lucas, G.S., et al. A Gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 358 (2008), 162–168.
10. Berra, E., Benizri, E., Ginouvès, A., et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J 22 (2003), 4082–4090.
11. Minamishima, Y.A., Moslehi, J., Bardeesy, N., et al. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 111 (2008), 3236–3244.
12. Percy, M.J., Zhao, Q., Flores, A., et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci USA 103 (2006), 654–659.
13. LeBleu, V.S., Taduri, G., O'Connell, J., et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med 19 (2013), 1047–1053.
14. Souma, T., Yamazaki, S., Moriguchi, T., et al. Plasticity of renal erythropoietin-producing cells governs fibrosis. J Am Soc Nephrol 24 (2013), 1599–1616.
15. Souma, T., Nezu, M., Nakano, D., et al. Erythropoietin synthesis in renal myofibroblasts is restored by activation of hypoxia signaling. J Am Soc Nephrol 27 (2016), 428–438.
16. Besarab, A., Chernyavskaya, E., Motylev, I., et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol 27 (2016), 1225–1233.
17. Besarab, A., Provenzano, R., Hertel, J., et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant 30 (2015), 1665–1673.
18. Provenzano, R., Besarab, A., Sun, C.H., et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin J Am Soc Nephrol 11 (2016), 982–991.
19. Pergola, P.E., Spinowitz, Hartman, C.S., et al. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int 90 (2016), 1115–1122.
20. Liu, Q., Davidoff, O., Niss, K., Haase, V.H., Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest 122 (2012), 4635–4644.
21. Chen, R.L., Ogunshola, O.O., Yeoh, K.K., et al. HIF prolyl hydroxylase inhibition prior to transient focal cerebral ischaemia is neuroprotective in mice. J Neurochem 131 (2014), 177–189.
22. Vogler, M., Zieseniss, A., Hesse, A.R., et al. Pre- and post-conditional inhibition of prolyl-4-hydroxylase domain enzymes protects the heart from an ischemic insult. Pflugers Arch 467 (2015), 2141–2149.
23. Bernhardt, W.M., Gottmann, U., Doyon, F., et al. Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model. Proc Natl Acad Sci USA 106 (2009), 2176–2181.
24. Rahtu-Korpela, L., Karsikas, S., Hörkkö, S., et al. HIF prolyl 4-hydroxylase-2 Inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction. Diabetes 63 (2014), 3324–3333.
25. Klotzsche-von Ameln, A., Muschter, A., Mamlouk, S., et al. Inhibition of HIF prolyl hydroxylase-2 blocks tumor growth in mice through the antiproliferative activity of TGFβ. Cancer Res 71 (2011), 3306–3316.
26. Kuchnio, A., Moens, S., Bruning, U., et al. The cancer cell oxygen sensor PHD2 promotes metastasis via activation of cancer-associated fibroblasts. Cell Rep 12 (2015), 992–1005.
27. Mazzone, M., Dettori, D., de Oliveira, R.L., et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136 (2009), 839–851.
28. Madsen, C.D., Pedersen, J.T., Venning, F.A., et al. Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis. EMBO Rep 16 (2015), 1394–1408.
29. Ang, S.O., Chen, H., Hirota, K., et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 32 (2002), 614–621.
30. Gale, D.P., Harten, S.K., Reid, C.D.L., et al. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2α mutation. Blood 112 (2008), 919–921.
31. Holdstock, L., Meadowcroft, A.M., Maier, R., et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol 27 (2016), 1234–1244.
32. Tanaka, T., Kijima, I., Ohse, T., et al. Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. Lab Invest 85 (2005), 1292–1307.
33. Higgins, D.F., Kimura, K., Bernhardt, W.M., et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 117 (2007), 3810–3820.
34. Schietke, R.E., Hackenbeck, T., Tran, M., et al. Renal tubular HIF-2α expression requires VHL inactivation and causes fibrosis and cysts. PLoS ONE, 7, 2012, e31034.
35. ClinicalTrials.gov. Available at: https://clinicaltrials.gov. Accessed January 2, 2017.
36. Macdougall, I.C., Akizawa, T., Berns, J., et al. Erythropoiesis stimulating agents (ESA)–naïve anaemic patients with chronic kidney disease not on dialysis (CKD-ND). Nephrol Dial Transplant 31 (2016), i15–i17.
37. Macdougall, I.C., Akizawa, T., Berns, J., et al. Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND). Nephrol Dial Transplant 31 (2016), i193–i199.
38. Akizawa, T., Hanaki, K., Arai, M., JTZ-951, an oral novel HIF-PHD inhibitor, elevates hemoglobin in Japanese anemic patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant 30 (2015), iii195–iii204.
39. Olson, E., Demopoulos, L., Haws, T.F., et al. Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease. Vasc Med 19 (2014), 473–482.
40. Mokas, S., Larivière, R., Lamalice, L., et al. Hypoxia-inducible factor-1 plays a role in phosphate-induced vascular smooth muscle cell calcification. Kidney Int 90 (2016), 598–609.